Axona (Accera) review shows benefits for Alzheimer's

Results of a retrospective review of 55 patients taking Axona (caprylic triglyceride), from Accera, for a crucial aspect of Alzheimer's Disease (AD) known as diminished cerebral glucose metabolism (DCGM), have been published in Neuropsychiatric Disease and Treatment. Results from the study suggest that administration of Axona in patients with mild-to-moderate AD helped stabilize or improve the clinical status and cognitive function in patients receiving this therapy for an average of approximately 19 months.

Physician's Overall Assessment of Changes from baseline indicated that nearly 80% of patients either showed improvement or remained stable. Caregiver assessments also indicated stability or improvement for cognitive function and no significant changes in the ability to carry out activities of daily living. See: "Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate Alzheimer's disease" Maynard SD, Gelblum J. Neuropsychiatric Disease and Treatment, Oct 2013 Vol 2013:9 P1619 - 1627 DOI: http://dx.doi.org/10.2147/NDT.S52331